1) To Identify the Concentration of CD That Provides Optimal Bioavailability of a Concomitant Fixed Concentration of LD Infused SC Continuously; 2) To Compare the Bioavailability of the Optimal LD/CD Solution to That of LD/CD Intestinal Gel

Trial Profile

1) To Identify the Concentration of CD That Provides Optimal Bioavailability of a Concomitant Fixed Concentration of LD Infused SC Continuously; 2) To Compare the Bioavailability of the Optimal LD/CD Solution to That of LD/CD Intestinal Gel

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2017

At a glance

  • Drugs Levodopa/carbidopa (Primary) ; Levodopa/carbidopa
  • Indications Parkinson's disease
  • Focus Pharmacokinetics
  • Sponsors NeuroDerm
  • Most Recent Events

    • 08 Jun 2017 Pooled results from two open-label, dose-finding studies assessing optimal carbidopa concentration in subcutaneously administered ND0612, presented at the 69th Annual Meeting of the American Academy of NeurologyResults presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
    • 08 Jun 2017 Results presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
    • 23 May 2017 According to a NeuroDerm media release, data from this trial will be presented at the 21st International Congress of Parkinson's Disease and Movement Disorders.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top